Cargando…
Allogeneic Mesenchymal Stromal Cells (MSCs) are of Comparable Efficacy to Syngeneic MSCs for Therapeutic Revascularization in C57BKSdb/db Mice Despite the Induction of Alloantibody
Intramuscular administration of mesenchymal stromal cells (MSCs) represents a therapeutic option for diabetic critical limb ischemia. Autologous or allogeneic approaches may be used but disease-induced cell dysfunction may limit therapeutic efficacy in the former. Our aim was to compare the efficacy...
Autores principales: | Liew, A., Baustian, C., Thomas, D., Vaughan, E., Sanz-Nogués, C., Creane, M., Chen, X., Alagesan, S., Owens, P., Horan, J., Dockery, P., Griffin, M. D., Duffy, A., O’Brien, T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6434464/ https://www.ncbi.nlm.nih.gov/pubmed/30016879 http://dx.doi.org/10.1177/0963689718784862 |
Ejemplares similares
-
The role of MSCs and CAR-MSCs in cellular immunotherapy
por: Yan, Lun, et al.
Publicado: (2023) -
iPSC-Derived MSCs Are a Distinct Entity of MSCs with Higher Therapeutic Potential than Their Donor-Matched Parental MSCs
por: Lee, Hae-Ri, et al.
Publicado: (2023) -
MSCs Become Collagen-Type I Producing Cells with Different Phenotype in Allogeneic and Syngeneic Bone Marrow Transplantation
por: Rusch, Robert Maximilian, et al.
Publicado: (2021) -
Immunomodulatory Effect of MSCs and MSCs-Derived Extracellular Vesicles in Systemic Lupus Erythematosus
por: Yang, Chunjuan, et al.
Publicado: (2021) -
TA-MSCs, TA-MSCs-EVs, MIF: their crosstalk in immunosuppressive tumor microenvironment
por: Zhang, Zhenghou, et al.
Publicado: (2022)